Prime

Type your tag names separated by a space and hit enter

Cannabinoids and cardiovascular disease: the outlook for clinical treatments.

Abstract

Cannabinoid drugs exert their effects primarily through activation of cannabinoid CB1 and CB2 receptors. Both CB1 and CB2 receptors have been implicated in a number of cardiovascular processes, including vasodilation, cardiac protection, modulation of the baroreceptor reflex in the control of systolic blood pressure, and inhibition of endothelial inflammation and the progress of atherosclerosis in a murine model. These effects are mainly mediated through central and peripheral nervous system CB1 receptors, vascular CB1 receptors and immune cell CB2 receptors. Relevant cellular effects include: the inhibition of neurotransmitter release in the nucleus tractus solitarius and in peripheral adrenergic neurons; regulation of NOS activity in vascular beds; inhibition of vascular smooth muscle cell excitability; regulation of endothelial cell migration and proliferation; and effects on immune cell proliferation, activation, and inflammatory functions. We review the pre-clinical evidence for beneficial effects of cannabinoid drugs in a range of vascular and cardiovascular pathologies. We also discuss the clinically relevant potential of cannabinoids.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors

    Ashton JC, Smith PF

    Source

    Current vascular pharmacology 5:3 2007 Jul pg 175-85

    MeSH

    Animals
    Anti-Obesity Agents
    Cannabinoid Receptor Modulators
    Cannabinoids
    Cardiovascular Agents
    Cardiovascular Diseases
    Cardiovascular System
    Humans
    Obesity
    Piperidines
    Pyrazoles
    Receptor, Cannabinoid, CB1
    Receptor, Cannabinoid, CB2
    Risk Factors
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    17627561